- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.04. | Aelis Farma: Availability of the 2023 Universal Registration Document | 156 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication... ► Artikel lesen | |
| 18.04. | Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder | 185 | Business Wire | The last patient in the clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder has completed its last medical visit, paving the way for the release of study results in... ► Artikel lesen | |
| 02.04. | Aelis Farma Reports Its 2023 Annual Financial Results and Confirms Its 2024 Outlook | 248 | Business Wire | 2023 has been marked by key milestones for the Company's two drug candidates: AEF0117: completion of patient recruitment for the phase 2b study with 333 patients in excessive cannabis... ► Artikel lesen | |
| 30.01. | Aelis Farma Announces Its 2024 Financial Calendar | 309 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its... ► Artikel lesen | |
| 17.01. | Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer | 462 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders, today... ► Artikel lesen | |
| 09.01. | Aelis Farma completes patient enrollment for cannabis addiction study | 1 | Investing.com | ||
| 09.01. | Aelis Farma Announces Completion of Patient Randomization for Phase 2b Study with AEF0117 for the Treatment of Cannabis Addiction | 418 | Business Wire | As planned, 333 patients have been randomized at end of December 2023 across 11 clinical centers in the United States This major milestone confirms the announced availability of the first... ► Artikel lesen | |
| 07.11.23 | Aelis Farma Announces Positive Results of Non-clinical Studies Required by Regulatory Agencies to Enter Its First CB1-SSi, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder | 385 | Business Wire | Positive results of in vivo toxicology studies in which AEF0117 shows a favorable therapeutic index >13,000 time the active dose: Chronic oral toxicity studies (6 months in rats and... ► Artikel lesen | |
| 26.09.23 | Aelis Farma: Availability of the 2023 Half-Year Financial Report | 325 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year... ► Artikel lesen | |
| 25.09.23 | Aelis Farma Publishes Half-Year Financial Results for 2023 and Confirms Its Development Objectives | 377 | Business Wire | Acceleration of recruitment in AEF0117 phase 2b trial for the treatment of cannabis addiction and approval obtained in July 2023 by an independent Data Safety Monitoring Board (DSMB) to continue... ► Artikel lesen | |
| 28.08.23 | Pier Vincenzo Piazza, CEO of Aelis Farma, Receives the Distinguished Achievement Award from the European Behavioural Pharmacology Society (EBPS) | 362 | Business Wire | The Award rewards Pier Vincenzo Piazza's contribution to the advancement of research in the field of neuroscience
Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage... ► Artikel lesen | |
| 20.07.23 | Aelis Farma Takes Part in the 10th Edition of the Gordon Research Conference on the Role of Cannabinoid Receptors in Central Nervous System Disorders | 432 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces its participation... ► Artikel lesen | |
| 05.07.23 | Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction | 502 | Business Wire | The compound's favorable safety and tolerability profile allows to confidently continue the phase 2b of AEF0117, with the first results expected in mid-2024
Regulatory News:
Aelis Farma (ISIN:... ► Artikel lesen | |
| 21.06.23 | Aelis Farma: Availability of the Description of the Share Buyback Program | 546 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that the... ► Artikel lesen | |
| 12.06.23 | Aelis Farma: Preclinical Data Demonstrating the Efficacy of AEF0217 in a Genetic Mouse Model of Autism Spectrum Disorder Has Been Presented at the 2nd European Conference on Phelan-McDermid Syndrome | 352 | Business Wire | The 2nd European Conference on Phelan-McDermid Syndrome was held in Madrid from June 9 to 11, 2023
Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 08.06.23 | Nature Medicine Publishes Discovery of New Pharmacological Class by Aelis Farma, Phase 2a Study of First Drug Candidate for Cannabis Use Disorder | 524 | Business Wire | Cannabis use disorder (CUD) affects over 14 million individuals in the US Despite the urgent need, there are no FDA-approved medications to treat CUD; behavioral treatments have shown limited... ► Artikel lesen | |
| 25.05.23 | Results of Aelis Farma Combined General Meeting of May 24, 2023 | 359 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that all... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Evotec vor Übernahme? Ausblick 2024 im Detail | Der Versuch der Shortseller, die Evotec-Aktie (WKN: 566480) nach dem Kurssturz am vergangenen Mittwoch noch tiefer zu drücken, ist gescheitert. Die Equity Story des innovativen Hamburger Wirkstoffforschers... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
Das Unternehmen AELIS FARMA SAS kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 12,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
